Result for
Tag: vaccines
March 23, 2021
Reduced BNT162b2 MRNA Vaccine Response in SARS-CoV-2-Naive Nursing Home Residents
[Pre-print, not peer-reviewed] Nursing home (NH) residents had blunted antibody responses following vaccination with BNT162b2 mRNA vaccine (Moderna) when compared to healthcare workers. SARS-CoV-2-naive NH residents mounted antibody responses with nearly 4-fold lower median neutralization titers and half the anti-spike level compared to SARS-CoV-2-naive healthcare workers. In contrast, NH residents who had recovered from infection…
March 17, 2021
County-Level COVID-19 Vaccination Coverage and Social Vulnerability — United States, December 14, 2020–March 1, 2021
Counties with high social vulnerability had lower first-dose vaccination coverage (14%) compared to those with low social vulnerability (16%) during the first 2.5 months of the SARS-CoV-2 vaccination program in the US (December 15, 2020 – March 1, 2021). Vaccination coverage was lower in low vulnerability counties compared to high vulnerability counties among those aged…
Associations of the BNT162b2 COVID-19 Vaccine Effectiveness with Patient Age and Comorbidities
[Pre-print, not peer-reviewed] Effectiveness of the Pfizer-BioNTech vaccine gradually increased starting at 12 days after the first vaccine dose and then plateaued around 35 days, according to an analysis of electronic health records from 1.79 million individuals in Israel. This period of maximum effectiveness corresponds to a period 2-weeks after the scheduled administration of the…
Efficacy of the ChAdOx1 NCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 among people infected with the B.1.351 variant in a multicenter randomized trial in South Africa. Mild-to-moderate COVID-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9%. Among the…
March 12, 2021
Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract
Receipt of the 13-valent pneumococcal conjugate vaccine (PCV13) was associated with lower incidence of any COVID-19 diagnosis, COVID-19 hospitalization, and fatal COVID-19 hospitalization after accounting for potential sources of confounding, according to a cohort study of 531,033 US adults aged ≥65 years. Lewnard et al. (Mar 9, 2021). Prevention of COVID-19 among older adults receiving pneumococcal…
ChAdOx1 nCoV-19 (AZD1222) protects against SARS-CoV-2 B.1.351 and B.1.1.7
[Pre-print, not peer-reviewed] An investigation of the Oxford-AstraZeneca (ChAdOx1 nCoV-1; AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in Syrian hamsters showed a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 did not lose weight compared to…
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
[Press release, not peer-reviewed] A Phase 3 trial of the Novavax vaccine (NVX‑CoV2373) in the UK indicated an efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain. The company also announced final results of its Phase 2b trial conducted in South Africa, with an efficacy of 55.4% among HIV-negative…
Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
The risk of asymptomatic SARS-CoV-2 infection was significantly lower among patients who had received at least 1 dose of an mRNA COVID-19 vaccine compared to unvaccinated patients, based on a retrospective cohort study of asymptomatic adult patients (n=39,156) across multiple US states undergoing a pre-procedural SARS-CoV-2 molecular screening test. SARS-CoV-2 was detected in 3% of…
March 11, 2021
Epidemiological and Evolutionary Considerations of SARS-CoV-2 Vaccine Dosing Regimes
An immuno-epidemiological model suggests that a one-dose vaccination strategy would likely decrease short-term SARS-CoV-2 infections. Long-term outcomes, as well as likelihood of viral evolution driven by partial immunity, are mainly driven by relative immune robustness of one versus two doses. [EDITORIAL NOTE: A pre-print related to this manuscript was summarized on February 4, 2020] Saad-Roy…
March 10, 2021
Vaccine Effectiveness after 1st and 2nd Dose of the BNT162b2 MRNA Covid-19 Vaccine in Long-Term Care Facility Residents and Healthcare Workers – a Danish Cohort Study
[Pre-print, not peer-reviewed] A retrospective registry- and population-based observational cohort study in Denmark estimated that the Pfizer/BioNTech vaccine efficacy within 7 days of receipt was 52% among long term care facility residents (LTCF, n = 39,040) and 46% among health care workers (HCW, n = 331,039), which increased to 64% and 90%, respectively, beyond 7…
Previous page Next page